Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.02.025 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Therapy, 2025. Verfasst von Dorothea Holzwarth und 14 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital in Bonn, 53127 Bonn, Germany. Electronic address: dorothea.holzwarth@ukbonn.de. Hauptthemen laut MEDLINE: Astrocytoma, Biological Products, Dependovirus, Genetic Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Gene Therapies Inc.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a severe neuromuscular disease, leading to progressive muscle weakness and potentially early mortality if untreated. Onasemnogene abeparvovec is a recombinant adeno-associated virus serotype 9 (rAAV9)-based gene therapy that has demonstrated improvements in survival and motor function for SMA patients. Here, we present a case of a patient diagnosed with a grade 1 pilocytic astrocytoma at the age of 2 years, approximately 8 months after onasemnogene abeparvovec treatment. Although vector genomes delivered by rAAVs persist primarily as episomes, rare integration events have been linked to tumor formation in neonate murine models. Therefore, we investigated the presence and possible integration of onasemnogene abeparvovec in formalin-fixed paraffin embedded (FFPE) and frozen tumor samples. In situ hybridization demonstrated variable transduction levels in individual tumor cells, while droplet digital PCR measured an average vector copy number ranging from 0.7 to 4.9 vector genomes/diploid genome. Integration site analysis identified a low number of integration sites that were not conserved between technical replicates, nor between FFPE and frozen samples, indicating that cells hosting integrating vector genomes represented a minority in the overall cell population. Thus, molecular analysis of the tumor tissue suggests that tumorigenesis was causally independent of the administration of onasemnogene abeparvovec.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Children's Hospital in Bonn, 53127 Bonn, Germany. Electronic address: dorothea.holzwarth@ukbonn.de.
- University Children's Hospital in Bonn, 53127 Bonn, Germany.
- Pediatric Neurology, Karolinska University Hospital, 171 77 Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institute, 171 77 Stockholm, Sweden.
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
- Novartis BioMedical Research, Cambridge, MA 02139, USA.
- Novartis BioMedical Research, 4056 Basel, Switzerland.
Förderung
- Novartis Gene Therapies Inc
Zitieren
APA
Holzwarth, D., Calaminus, G., Friese, J., Sejersen, T., Büning, H., John-Neek, P., Bastone, A. L., Rothe, M., Mansfield, K., Libertini, S., Dubost, V., Kuzmiski, B., Alecu, I., Labik, I., & Kirschner, J. (2025). Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.02.025
Vancouver
Holzwarth D, Calaminus G, Friese J, Sejersen T, Büning H, John-Neek P, et al. Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.02.025
BibTeX
@article{Holzwarth2025,
author = {Holzwarth, Dorothea and Calaminus, Gabriele and Friese, Johannes and Sejersen, Thomas and Büning, Hildegard and John-Neek, Philipp and Bastone, Antonella Lucía and Rothe, Michael and Mansfield, Keith and Libertini, Silvana and Dubost, Valérie and Kuzmiski, Brent and Alecu, Iulian and Labik, Ivan and Kirschner, Janbernd},
title = {Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.02.025}
}
EUVIMED